Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 3Thoracic 1Other solid neoplasm 1Myeloid 1Endocrine 1Dermatologic 1

Conditions

Carcinoma, Merkel Cell 21Melanoma 9Carcinoma, Non-Small-Cell Lung 7Squamous Cell Carcinoma of Head and Neck 6Carcinoma, Renal Cell 6Urinary Bladder Neoplasms 5Stomach Neoplasms 4Neoplasm Metastasis 4Triple Negative Breast Neoplasms 3Small Cell Lung Carcinoma 3Skin Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Uveal Melanoma 1Turcot syndrome 1Sezary Syndrome 1Sarcoma 1Primary Myelofibrosis 1Mycosis Fungoides 1Motor Activity 1Microsatellite Instability 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, T-Cell, Cutaneous 1

Interventions

Peripheral Blood Stem Cell Transplantation 42fludarabine phosphate 37Cyclophosphamide 36Mycophenolic Acid 28Whole-Body Irradiation 26Cyclosporine 25Busulfan 25Tacrolimus 22Antilymphocyte Serum 21Methotrexate 16Filgrastim 16Etoposide 15Methylprednisolone 13Melphalan 13Radiotherapy 12Flow Cytometry 11Psychiatric Rehabilitation 10Therapeutics 9Rituximab 9Polymerase Chain Reaction 8Bortezomib 8Gemcitabine 7Cord Blood Stem Cell Transplantation 7sargramostim 6Vorinostat 6Sirolimus 6tanespimycin 5Transplantation 5Thiotepa 5Carboplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × avelumab × Dermatologic × Clear all
NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

iOnctura

Phase 1 Active not recruiting
210 enrolled
DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡